Portugal is set to participate in an international clinical trial evaluating a novel targeted therapy for head and neck cancers, marking a significant step in the country’s contribution to advanced oncological research. The investigational treatment, known as amivantamab, is a bispecific antibody designed to interfere with key molecular pathways involved in tumour growth and survival.
The upcoming phase of research will involve multiple hospitals across Portugal, reflecting a broader global effort to assess the therapy’s safety and efficacy in a larger patient population. Clinical trials are expected to include individuals diagnosed with advanced or inoperable forms of head and neck cancer, a group for whom treatment options are often limited.
Head and neck cancers represent a substantial public health challenge in Portugal, where thousands of new cases are identified annually. Epidemiological evidence indicates that a significant proportion of patients are diagnosed at later stages of the disease, which is associated with reduced survival rates and more complex treatment pathways. According to European cancer statistics, delayed diagnosis remains a persistent issue across the region.
The investigational drug operates through a dual-target mechanism, binding simultaneously to epidermal growth factor receptor (EGFR) and mesenchymal–epithelial transition (MET) pathways. Both are known to play critical roles in tumour proliferation and resistance to conventional therapies. By targeting these pathways, the treatment aims not only to inhibit tumour growth but also to enhance the body’s immune response against malignant cells.
Preliminary findings presented at international oncology conferences, including meetings organised by the American Society of Clinical Oncology (ASCO), have demonstrated encouraging outcomes. In early-stage trials involving just over one hundred participants, a notable proportion experienced measurable tumour reduction, with some cases showing complete response. These results, while still requiring validation in larger cohorts, suggest potential for meaningful clinical benefit.
The method of administration also represents a shift from traditional intravenous therapies. Delivered via subcutaneous injection at regular intervals, the treatment may offer improved convenience and reduced burden for patients, aligning with ongoing efforts to enhance quality of care in oncology.
Safety data from initial trials indicate that most adverse effects have been manageable, with relatively low discontinuation rates. This profile is consistent with other targeted therapies, although long-term safety and efficacy remain under investigation.
Amivantamab is already being studied in other malignancies, including lung cancer, where it has shown activity in patients with specific genetic mutations. Ongoing research across multiple tumour types highlights the growing importance of precision medicine, which seeks to tailor treatments based on the biological characteristics of individual cancers.
The inclusion of Portugal in this international trial underscores the country’s expanding role in clinical research and its commitment to providing patients with access to innovative therapies. Participating institutions will contribute to data collection and analysis, helping to determine whether this new approach can become part of standard treatment protocols in the future.
Experts emphasise that while these findings are promising, further investigation is essential before widespread clinical adoption. Nonetheless, the development of therapies targeting multiple cancer pathways simultaneously represents a promising direction in oncology, with the potential to improve outcomes for patients facing complex and advanced disease.
As research progresses, the integration of novel biologic treatments such as amivantamab may play an increasingly important role in addressing unmet needs in cancer care, both in Portugal and globally.